Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alvotech's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-13,371 Mil. Alvotech's Revenue for the
three
months ended in Mar. 2026 was kr13,275 Mil. Therefore, Alvotech's FCF Margin % for the quarter that ended in Mar. 2026 was -100.72%.
The historical rank and industry rank for Alvotech's FCF Margin % or its related term are showing as below:
OISE:ALVO'
s FCF Margin % Range Over the Past 10 Years
Min: -731 Med: -302.65 Max: -24.96
Current: -43.28
During the past 7 years, the highest FCF Margin % of Alvotech was -24.96%. The lowest was -731.00%. And the median was -302.65%.
OISE:ALVO's FCF Margin % is ranked worse than 88.27% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs OISE:ALVO: -43.28
Alvotech FCF Margin % Related Terms
Alvotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Alvotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OISE:ALVO vs PAHC, COLL, XERS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Alvotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (OISE:ALVO) has a FCF Margin % of -100.72% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alvotech and its competitors. According to the industry distribution chart, Alvotech ranks #850 out of 963 companies in the Drug Manufacturers industry, placing it in the top 88.3%.
Is Alvotech's FCF Margin % too high?
Alvotech's current FCF Margin % is -100.72%. Based on the distribution chart, Alvotech ranks #850 out of 963 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's FCF Margin % compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #850 out of 963 companies for FCF Margin %. This places Alvotech in the lower half of its industry. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alvotech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current FCF Margin % is -100.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,324.01, compared to a current price of kr409.00 — trading 82.4% below its estimated fair value. The current FCF Margin % is -100.72%. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current FCF Margin % is -100.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (OISE:ALVO) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of kr409.00 is trading 82.4% below its estimated GF Value™ of kr2,324.01.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for OISE:ALVO:
FCF Margin %: -100.72%
GF Value™: kr2,324.01 vs. price of kr409.00 (82.4% below fair value)
No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score
Get the complete analysis for OISE:ALVO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:ALVO has been successfully added to your 
